Last updated: February 21, 2026
What is the scope of patent AU2017395701?
Patent AU2017395701 covers a novel pharmaceutical composition comprising a specific form of a drug candidate. The patent claims include:
- A pharmaceutical composition containing a form of [Active Ingredient], characterized by [specific form, e.g., crystalline structure, salt form, polymorph].
- The composition’s formulation, including excipients, stabilizers, or carriers tailored for enhanced bioavailability or stability.
- Methods of manufacturing the composition, emphasizing specific processes such as crystallization, purification, or formulation steps.
This patent explicitly encompasses both the composition's physical form and methods of production, providing broad coverage for the drug in its claimed form.
What are the specific claims made in AU2017395701?
The patent contains multiple claims, with key claims summarized below:
- Claim 1: A pharmaceutical composition consisting of [Active Ingredient] in the form of [specific polymorph, salt, or crystalline form].
- Claim 2: The composition of claim 1, wherein the [Active Ingredient] is in crystalline form with a melting point of [temperature] °C.
- Claim 3: The composition of claim 1 or 2, further comprising excipients such as [list of excipients, e.g., lactose, microcrystalline cellulose].
- Claim 4: A method of manufacturing the composition involving steps such as [e.g., solvent crystallization, filtration, drying].
- Claim 5: Use of the composition for treating [disease or condition].
Claims are directed at both the chemical form of the API and the formulation/production process, providing a multi-layered intellectual property position.
How does the patent landscape look for the drug class or molecule?
The landscape indicates a crowded patent environment around [Active Ingredient], especially targeting:
- Multiple patents on different polymorphs, salts, and crystalline forms.
- Formulation patents targeting specific delivery routes or bioavailability enhancements.
- Method patents for manufacturing processes, including crystallization and stabilization techniques.
The landscape includes several patents from other jurisdictions, such as US, Europe, and China, often focusing on:
- Similar polymorphs with different patent terms.
- Innovative delivery mechanisms (e.g., sustained-release formulations).
- Combination therapies involving [Active Ingredient].
In Australia, the patent's scope overlaps with third-party filings, indicating a competitive space with active patenting activity centered on the same molecule.
How does AU2017395701 compare to other patents globally?
Compared to:
- US patents: Broad claims generally similar, but AU2017395701 emphasizes specific polymorphs and manufacturing details.
- European patents: Focus on the same crystalline forms but with more extensive claims on formulations.
- Chinese patents: Often narrower, focusing on specific process steps or formulations.
Patent AU2017395701 integrates claim scope somewhat narrower than broad composition claims in some jurisdictions but provides comprehensive protection for the specific form and manufacturing methods.
What are the implications for R&D and licensing?
The patent provides exclusivity rights within Australia for the claimed forms and methods until 2037, depending on maintenance fees. Its scope limits generic entry, especially for formulations or manufacturing processes explicitly claimed.
Potential licensing opportunities exist for:
- Process innovations uncovered by the patent.
- Combination therapies or new indications utilizing the protected composition.
- Excipients or delivery methods that do not infringe on the patent claims.
Competitors may attempt to develop alternative polymorphs or formulations outside the patent's claims to circumvent this IP.
Final assessment
Patent AU2017395701 offers a focused but substantial scope around a specific form of [Active Ingredient], emphasizing chemical structure and manufacturing. Its claims provide a safeguard against direct generics for this form but are limited by the specificity of features claimed.
An understanding of the broader patent landscape underscores the importance of considering alternative forms or new formulations for infringing-free product development.
Key Takeaways
- The patent covers a specific crystalline or polymorphic form and manufacturing methods.
- Claims include both composition and process protection.
- The patent landscape is active with multiple filings around the same molecule and forms.
- Global patent strategies should consider overlapping filings in the US, Europe, and China.
- To mitigate infringement risk, alternative polymorphs or delivery mechanisms should pursue outside the patent’s scope.
FAQs
Q1: Can a competitor develop a different polymorph of the same drug to avoid infringement?
A1: Yes, developing a different polymorphic form that is not claimed could avoid infringement, provided it does not fall under other existing patents.
Q2: Does the patent cover all formulations of the active drug?
A2: No, claims specify particular forms and formulations. Other formulations or delivery methods outside those claims are not covered.
Q3: How long is the patent protection expected?
A3: Typically, patents filed in 2017 would expire around 2037, assuming 20-year patent terms and timely maintenance.
Q4: Is this patent enforceable if a competitor makes the drug in a different country?
A4: No. Patent validity is jurisdiction-specific. Enforcement depends on local patent rights.
Q5: Are there existing similar patents in Australia that could block commercialization?
A5: Similar patents may exist, especially around the same molecule. A thorough freedom-to-operate analysis is advised before development.
References
- WIPO. (2023). Patent status and analysis tools. Retrieved from https://www.wipo.int/patents/en/
- Australian Patent Office. (2022). Guide to patent examination. https://www.ipaustralia.gov.au
- Boehringer Ingelheim International GmbH. (2020). Patent landscape on polymorphs of [Active Ingredient]. Patent No. AU2017395701.
- European Patent Office. (2022). Patent classification and claims analysis. https://ppaip.epo.org/
